Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of selective small-molecule mRNA drugs and their mechanisms of action. The company combines high-scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using artificial intelligence to elucidate the mechanism of action of active molecules.
This level of automation of phenotypic screening of mRNA modulators together with its AI-driven MOA elucidation has enabled Anima Biotech to develop a broad pipeline across 18 different discovery programs in various therapeutic areas.
Anima's wholly owned pipeline programs are in fibrosis (collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), oncology (c-Myc mRNA biology modulators and mutation-agnostic mKras mRNA biology modulators), and neuroscience (Tau; Alzheimer's disease and pain; Nav1.7 mRNA biology modulators).
In addition, Anima established strategic collaborations with the pharmaceutical industry in partnered programs including Lilly, Takeda Pharmaceuticals, and Abbvie.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Anima Biotech Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jan 17, 2023
www.genengnews.com
AbbVie to Develop mRNA Modulators Using Anima Biotech Platform
#Partners #Investment
Jan 10, 2023
news.abbvie.com
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
#Partners, Investment
Dec 14, 2022
www.globenewswire.com
Anima Biotech To Present And Participate In Panel Discussion At The 5th RNA Targeted Drug Discovery Summit
#Partners #Investment
Jul 20, 2022
www.globenewswire.com
Anima Biotech Achieves Milestone in Takeda Collaboration
#Partners
Apr 19, 2022
finance.yahoo.com
Anima Biotech to Present at the 3rd Annual RNA-Targeting Small Molecule Drugs Conference